Session Information

WCLC 2017

18th World Conference on Lung Cancer

Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan

Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.
Presentation Date(s):
- Oct 15 - 18, 2017
- Total Presentations: 2295
Register to Attend WCLC Return to WCLC 2017 Website Switch to Virtual Meeting
Enter Virtual Meeting Access Code

All Days Saturday
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18

Filter Results:

Show Only CME Accredited Sessions

18982

+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- 07:30 - 11:30
- 10/15/2017
- Location: F203 (Annex Hall)
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Moderators:C. Bai, Fred R. Hirsch, Tony SK Mok, Yi-Long Wu
- 22310
  
  +
  
  JCSE 01.18 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
  
  11:30 - 11:30 | Presenter: Yun Fan | Author(s): K. Chen, X. Yu, H. Wang, Z. Huang, Y. Xu, L. Gong
  Abstract
  
  Loading...
18971

+
P1.02 - Biology/Pathology
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- 22530
  
  +
  
  P1.02-046 - Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations
  
  09:30 - 09:30 | Presenter: Gang Chen | Author(s): Chunwei Xu, W. Wang, Wu Zhuang, Z. Huang, Z. Song, Y. Chen, W. Liu, Rongrong Chen, Y. Guan, X. Yi, Meiyu Fang, T.F. Lv, Yong Song
  Abstract
  
  Loading...
20167

+
P2.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/17/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- 23284
  
  +
  
  P2.03-013 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
  
  09:30 - 09:30 | Presenter: Yun Fan | Author(s): K. Chen, X. Yu, H. Wang, Z. Huang, Y. Xu, L. Gong
  Abstract
  
  Loading...
20137

+
MA 07 - ALK, ROS and HER2
- 15:45 - 17:30
- 10/17/2017
- Location: Room 316
- Type: Mini Oral
- Track: Advanced NSCLC
- Moderators:Robert C. Doebele, J.C. Ho
- 23703
  
  +
  
  MA 07.09 - ALK/ROS1/TRK Inhibitor TPX-0005 Effectively Overcomes Clinical Resistance Solvent Front Mutations
  
  16:35 - 16:40 | Presenter: J. Jean Cui | Author(s): D. Zhai, W. Deng, E. Rogers, J. Ung, X. Zhang, H. Zhang, Z. Huang, J. Whitten, J. Lim, Y. Li
  Abstract
  
  Loading...
18975

+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- 23867
  
  +
  
  P3.01-008 - Association between Icotinib Efficacy and Circulating Tumor Cell Levels in Advanced Non-Small Cell Lung Cancer
  
  09:30 - 09:30 | Presenter: Meiyu Fang | Author(s): Y. Huang, W. Wang, Chunwei Xu, Wu Zhuang, Z. Song, Z. Huang, G. Lin, X. Chen, B. Wu, Y. Chen, Gang Chen
  Abstract
  
  Loading...
18974

+
P3.02 - Biology/Pathology
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- 23976
  
  +
  
  P3.02-028 - 276 Cases of EGFR/ALK Gene Status and Predominant Histologic Subtype in Chinese Surgically Resected Lung Adenocarcinoma
  
  09:30 - 09:30 | Presenter: Gang Chen | Author(s): Z. Huang, Chunwei Xu, W. Wang, Wu Zhuang, Z. Song, Y. Chen, Meiyu Fang, T.F. Lv, Yong Song
  Abstract
  
  Loading...
20182

+
P3.03 - Chemotherapy/Targeted Therapy
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- 24075
  
  +
  
  P3.03-030 - TP53 Alteration, a Potential Primary Cause of Early Progression in EGFR-Mutated NSCLC Patients Treated with First-Line TKIs
  
  09:30 - 09:30 | Presenter: Yun Fan | Author(s): Y. Xu, Z. Huang, H. Lu
  Abstract
  
  Loading...
- 24076
  
  +
  
  P3.03-031 - Response to Crizotinib Can Occur in C-MET Overexpression NSCLC Independent of MET exon14 Alterations After First-Line EGFR-TKI Resistance
  
  09:30 - 09:30 | Presenter: Yun Fan | Author(s): Y. Xu, Z. Huang
  Abstract
  
  Loading...

Session Information

WCLC 2017

18th World Conference on Lung Cancer

Enter Virtual Meeting Access Code

+

JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West

+

JCSE 01.18 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

+

P1.02 - Biology/Pathology

+

P1.02-046 - Mutational Subtypes and Prognosis of Non-Small-Cell Lung Cancer Harboring HER2 Mutations

+

P2.03 - Chemotherapy/Targeted Therapy

+

P2.03-013 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

+

MA 07 - ALK, ROS and HER2

+

MA 07.09 - ALK/ROS1/TRK Inhibitor TPX-0005 Effectively Overcomes Clinical Resistance Solvent Front Mutations

+

P3.01 - Advanced NSCLC

+

P3.01-008 - Association between Icotinib Efficacy and Circulating Tumor Cell Levels in Advanced Non-Small Cell Lung Cancer

+

P3.02 - Biology/Pathology

+

P3.02-028 - 276 Cases of EGFR/ALK Gene Status and Predominant Histologic Subtype in Chinese Surgically Resected Lung Adenocarcinoma

+

P3.03 - Chemotherapy/Targeted Therapy

+

P3.03-030 - TP53 Alteration, a Potential Primary Cause of Early Progression in EGFR-Mutated NSCLC Patients Treated with First-Line TKIs

+

P3.03-031 - Response to Crizotinib Can Occur in C-MET Overexpression NSCLC Independent of MET exon14 Alterations After First-Line EGFR-TKI Resistance

Stay Connected